Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

 Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios’ Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion –

– Strong Cash Position to Enable Agios to Prepare for Potential PYRUKYND® (Mitapivat) Launches in Thalassemia in 2025 and Sickle Cell Disease in 2026 and Drive Pipeline Progress –

https://www.biospace.com/agios-to-receive-1-1-billion-in-milestone-payments-following-fda-approval-of-vorasidenib